Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome
HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS...
Saved in:
Published in | AIDS (London) Vol. 27; no. 13; pp. 2089 - 2099 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
24.08.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS could enable risk stratification.
Prospective, longitudinal cohort study for 24 weeks.
Durban, South Africa.
One hundred and thirty HIV-infected patients with first cryptococcal meningitis episode
: Antifungal therapy (amphotericin 1 mg/kg median 14 days, followed by consolidation and maintenance fluconazole) and cART (commenced median of 18 days from cryptococcal meningitis diagnosis).
Clinical, blood, and cerebrospinal fluid (CSF) markers associated with C-IRIS before and during cART and clinical significance of CSF cryptococcal culture negativity pre-cART commencement.
Of 106 patients commencing cART, 27 (25.5%) developed C-IRIS, 16 (15.1%) neurological deterioration-not C-IRIS, and 63 (59.4%) no neurological deterioration. On multivariable analysis, C-IRIS was associated with persistent CSF cryptococcal growth [hazard ratio (HR) 0.27, P=0.026] and lower CSF protein (HR 0.53, P=0.059) prior to cART and lower CD4 T-cell increases (HR 0.99, P=0.026) but not change in HIV viral load during cART. Using survival analysis, patients with a negative cryptococcal culture pre-cART commencement (n=51; 48.1%) experienced fewer episodes of neurological deterioration, C-IRIS, and cryptococcal relapse/persistence than patients with culture positivity (n=55; 51.9%, HR 0.33, 0.33, and 0.12 and P=0.0003, 0.0042, and 0.0004, respectively).
Persistent CSF cryptococcal growth at cART initiation and poor CD4 T-cell increases on cART are strong predictors of C-IRIS. Approaches aimed at achieving CSF culture negativity prior to cART should be evaluated as a strategy to reduce rates of C-IRIS. |
---|---|
AbstractList | OBJECTIVEHIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS could enable risk stratification.DESIGNProspective, longitudinal cohort study for 24 weeks.SETTINGDurban, South Africa.PARTICIPANTSOne hundred and thirty HIV-infected patients with first cryptococcal meningitis episodeINTERVENTION: Antifungal therapy (amphotericin 1 mg/kg median 14 days, followed by consolidation and maintenance fluconazole) and cART (commenced median of 18 days from cryptococcal meningitis diagnosis).MAIN OUTCOME MEASUREClinical, blood, and cerebrospinal fluid (CSF) markers associated with C-IRIS before and during cART and clinical significance of CSF cryptococcal culture negativity pre-cART commencement.RESULTSOf 106 patients commencing cART, 27 (25.5%) developed C-IRIS, 16 (15.1%) neurological deterioration-not C-IRIS, and 63 (59.4%) no neurological deterioration. On multivariable analysis, C-IRIS was associated with persistent CSF cryptococcal growth [hazard ratio (HR) 0.27, P=0.026] and lower CSF protein (HR 0.53, P=0.059) prior to cART and lower CD4 T-cell increases (HR 0.99, P=0.026) but not change in HIV viral load during cART. Using survival analysis, patients with a negative cryptococcal culture pre-cART commencement (n=51; 48.1%) experienced fewer episodes of neurological deterioration, C-IRIS, and cryptococcal relapse/persistence than patients with culture positivity (n=55; 51.9%, HR 0.33, 0.33, and 0.12 and P=0.0003, 0.0042, and 0.0004, respectively).CONCLUSIONPersistent CSF cryptococcal growth at cART initiation and poor CD4 T-cell increases on cART are strong predictors of C-IRIS. Approaches aimed at achieving CSF culture negativity prior to cART should be evaluated as a strategy to reduce rates of C-IRIS. HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS could enable risk stratification. Prospective, longitudinal cohort study for 24 weeks. Durban, South Africa. One hundred and thirty HIV-infected patients with first cryptococcal meningitis episode : Antifungal therapy (amphotericin 1 mg/kg median 14 days, followed by consolidation and maintenance fluconazole) and cART (commenced median of 18 days from cryptococcal meningitis diagnosis). Clinical, blood, and cerebrospinal fluid (CSF) markers associated with C-IRIS before and during cART and clinical significance of CSF cryptococcal culture negativity pre-cART commencement. Of 106 patients commencing cART, 27 (25.5%) developed C-IRIS, 16 (15.1%) neurological deterioration-not C-IRIS, and 63 (59.4%) no neurological deterioration. On multivariable analysis, C-IRIS was associated with persistent CSF cryptococcal growth [hazard ratio (HR) 0.27, P=0.026] and lower CSF protein (HR 0.53, P=0.059) prior to cART and lower CD4 T-cell increases (HR 0.99, P=0.026) but not change in HIV viral load during cART. Using survival analysis, patients with a negative cryptococcal culture pre-cART commencement (n=51; 48.1%) experienced fewer episodes of neurological deterioration, C-IRIS, and cryptococcal relapse/persistence than patients with culture positivity (n=55; 51.9%, HR 0.33, 0.33, and 0.12 and P=0.0003, 0.0042, and 0.0004, respectively). Persistent CSF cryptococcal growth at cART initiation and poor CD4 T-cell increases on cART are strong predictors of C-IRIS. Approaches aimed at achieving CSF culture negativity prior to cART should be evaluated as a strategy to reduce rates of C-IRIS. Objective: HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS could enable risk stratification. Design: Prospective, longitudinal cohort study for 24 weeks. Setting: Durban, South Africa. Participants: One hundred and thirty HIV-infected patients with first cryptococcal meningitis episode Intervention: Antifungal therapy (amphotericin 1 mg/kg median 14 days, followed by consolidation and maintenance fluconazole) and cART (commenced median of 18 days from cryptococcal meningitis diagnosis). Main outcome measure: Clinical, blood, and cerebrospinal fluid (CSF) markers associated with C-IRIS before and during cART and clinical significance of CSF cryptococcal culture negativity pre-cART commencement. Results: Of 106 patients commencing cART, 27 (25.5%) developed C-IRIS, 16 (15.1%) neurological deterioration-not C-IRIS, and 63 (59.4%) no neurological deterioration. On multivariable analysis, C-IRIS was associated with persistent CSF cryptococcal growth [hazard ratio (HR) 0.27, P = 0.026] and lower CSF protein (HR 0.53, P = 0.059) prior to cART and lower CD4 super(+) T-cell increases (HR 0.99, P = 0.026) but not change in HIV viral load during cART. Using survival analysis, patients with a negative cryptococcal culture pre-cART commencement (n = 51; 48.1%) experienced fewer episodes of neurological deterioration, C-IRIS, and cryptococcal relapse/persistence than patients with culture positivity (n = 55; 51.9%, HR 0.33, 0.33, and 0.12 and P = 0.0003, 0.0042, and 0.0004, respectively). Conclusion: Persistent CSF cryptococcal growth at cART initiation and poor CD4 super(+) T-cell increases on cART are strong predictors of C-IRIS. Approaches aimed at achieving CSF culture negativity prior to cART should be evaluated as a strategy to reduce rates of C-IRIS. |
Author | MOOSA, Mohamed-Yunus S DORASAMY, Afton A NDUNG'U, Thumbi ELLIOTT, Julian H OMARJEE, Saleha FRENCH, Martyn A SPELMAN, Tim CHANG, Christina C GOSNELL, Bernadett I COOVADIA, Yacoob LEWIN, Sharon R NARANBHAI, Vivek |
Author_xml | – sequence: 1 givenname: Christina C surname: CHANG fullname: CHANG, Christina C organization: Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia – sequence: 2 givenname: Afton A surname: DORASAMY fullname: DORASAMY, Afton A organization: Department of Medical Microbiology, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital Academic Complex, South Africa – sequence: 3 givenname: Sharon R surname: LEWIN fullname: LEWIN, Sharon R organization: Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia – sequence: 4 givenname: Martyn A surname: FRENCH fullname: FRENCH, Martyn A organization: Department of Clinical Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Perth, Australia – sequence: 5 givenname: Bernadett I surname: GOSNELL fullname: GOSNELL, Bernadett I organization: Department of Infectious Diseases, King Edward VIII Hospital, South Africa – sequence: 6 givenname: Julian H surname: ELLIOTT fullname: ELLIOTT, Julian H organization: Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia – sequence: 7 givenname: Tim surname: SPELMAN fullname: SPELMAN, Tim organization: Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia – sequence: 8 givenname: Saleha surname: OMARJEE fullname: OMARJEE, Saleha organization: HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa – sequence: 9 givenname: Vivek surname: NARANBHAI fullname: NARANBHAI, Vivek organization: HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa – sequence: 10 givenname: Yacoob surname: COOVADIA fullname: COOVADIA, Yacoob organization: Department of Medical Microbiology, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital Academic Complex, South Africa – sequence: 11 givenname: Thumbi surname: NDUNG'U fullname: NDUNG'U, Thumbi organization: HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa – sequence: 12 givenname: Mohamed-Yunus S surname: MOOSA fullname: MOOSA, Mohamed-Yunus S organization: Department of Infectious Diseases, King Edward VIII Hospital, South Africa |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27677637$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23525034$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkUuLFTEQhYOMOHdG_4FIbwQ3PVZSeXQvh-sTBkTQdZNOKhLpTu4k3Yv-97bOVcGNq6LgO3Woc67YRcqJGHvO4YZDb17fW38DI3AkFB1qLm3nH7EDlwZbpQy_YAcQum97NHDJrmr9DgAKuu4JuxSohAKUBzYdp5iis1Njk2_mzeUpf_u1nwr56JZcapND48p2WrLLzuUaa2trzS7ahXwT53lN1BRyOdUlLusSc2piCpOdZ7vrt6ZuyZc801P2ONip0rPzvGZf3739cvzQ3n16__F4e9c62YmlHVH1Co0OGjhZ1EJ0pDvD96c6gwhS9MJo60wIo1XaWyKHKIJXVgSkEa_Zq4e7p5LvV6rLMMfqaJpsorzWgZvdQaCU8H9U9mBAaZA7Kh9QV3KthcJwKnG2ZRs4DD8rGT7fvhn-rWSXvTg7rONM_o_odwc78PIM2LoHH4pNLta_nNHGaDT4AxKqmW8 |
CitedBy_id | crossref_primary_10_1093_cid_ciac853 crossref_primary_10_1093_ofid_ofv194 crossref_primary_10_1111_myc_12977 crossref_primary_10_1093_ofid_ofad078 crossref_primary_10_1093_ofid_ofad158 crossref_primary_10_1111_myc_13467 crossref_primary_10_1016_S1473_3099_20_30771_4 crossref_primary_10_1080_14656566_2021_1940954 crossref_primary_10_1586_14787210_2015_1029917 crossref_primary_10_1007_s11910_019_0993_0 crossref_primary_10_1071_MA14030 crossref_primary_10_1186_s12920_021_00914_1 crossref_primary_10_1371_journal_ppat_1006207 crossref_primary_10_1097_QAD_0000000000000200 crossref_primary_10_1097_QCO_0000000000000224 crossref_primary_10_1093_ofid_ofv157 crossref_primary_10_3390_jof4040139 crossref_primary_10_1111_imj_15590 crossref_primary_10_1016_j_eimc_2017_11_002 crossref_primary_10_1016_j_mib_2017_10_018 crossref_primary_10_1038_s41572_023_00472_z crossref_primary_10_1111_imr_12063 crossref_primary_10_1007_s11046_020_00512_2 crossref_primary_10_1093_infdis_jiy083 crossref_primary_10_1016_j_mycmed_2023_101364 crossref_primary_10_1128_mBio_00166_17 crossref_primary_10_1186_s12974_023_02717_w crossref_primary_10_1186_1476_0711_12_40 crossref_primary_10_1093_ofid_ofy157 crossref_primary_10_1007_s11908_013_0378_5 crossref_primary_10_1093_infdis_jit271 crossref_primary_10_1111_imj_12597 crossref_primary_10_1186_1471_2334_14_423 crossref_primary_10_1016_S1473_3099_16_00074_8 crossref_primary_10_4269_ajtmh_20_0028 crossref_primary_10_1093_infdis_jit388 crossref_primary_10_1093_mmy_myv104 crossref_primary_10_1097_QAI_0000000000001946 crossref_primary_10_1111_myc_13361 crossref_primary_10_1128_AAC_01299_15 crossref_primary_10_1016_j_mmcr_2014_12_003 crossref_primary_10_1097_ID9_0000000000000044 crossref_primary_10_1186_s12981_022_00444_5 crossref_primary_10_3390_jof3020028 crossref_primary_10_1007_s11904_024_00691_3 crossref_primary_10_1007_s40588_015_0016_0 crossref_primary_10_3390_jof2010001 crossref_primary_10_3390_jof5020042 crossref_primary_10_1002_eji_201545689 crossref_primary_10_1093_ofid_ofz369 crossref_primary_10_1007_s40588_018_0099_5 crossref_primary_10_1097_CM9_0000000000001191 crossref_primary_10_3390_life11020095 crossref_primary_10_1093_cid_ciad123 crossref_primary_10_1093_cid_ciad122 crossref_primary_10_1093_ofid_ofx032 crossref_primary_10_1080_14787210_2017_1285697 crossref_primary_10_1093_cid_cix598 crossref_primary_10_1093_infdis_jiv067 crossref_primary_10_1016_j_idc_2014_05_002 crossref_primary_10_1016_j_idcr_2022_e01554 crossref_primary_10_3389_fmed_2023_1192086 crossref_primary_10_1093_cid_ciu641 crossref_primary_10_1007_s11904_014_0213_0 crossref_primary_10_3390_microorganisms10122419 crossref_primary_10_1016_j_diagmicrobio_2014_09_006 crossref_primary_10_1002_jia2_25416 crossref_primary_10_1093_infdis_jiy448 crossref_primary_10_1093_infdis_jiy447 crossref_primary_10_1016_j_clineuro_2024_108423 crossref_primary_10_1016_j_idc_2021_03_012 crossref_primary_10_1097_QAD_0000000000001796 crossref_primary_10_1016_j_jns_2021_117453 crossref_primary_10_1016_j_eimce_2017_11_024 crossref_primary_10_1038_s41598_020_67031_4 crossref_primary_10_1016_j_trsl_2015_07_010 crossref_primary_10_1056_NEJMoa1312884 crossref_primary_10_1007_s40475_015_0046_y crossref_primary_10_1016_S1473_3099_23_00731_4 crossref_primary_10_3389_fmed_2021_626266 crossref_primary_10_1186_s12981_016_0126_7 crossref_primary_10_1089_aid_2017_0209 crossref_primary_10_1097_QCO_0000000000000315 crossref_primary_10_1097_COH_0000000000000109 crossref_primary_10_1007_s40588_016_0033_7 crossref_primary_10_1007_s40588_016_0035_5 crossref_primary_10_1016_j_jiac_2022_11_002 |
Cites_doi | 10.1093/cid/cit019 10.1086/605497 10.1086/652652 10.1086/593194 10.5694/mja12.10089 10.1097/01.aids.0000174450.70874.30 10.1046/j.1468-1293.2000.00012.x 10.1097/QAI.0b013e3181a56f2e 10.1097/QAD.0b013e3283536a93 10.1086/503903 10.1097/QAD.0b013e328322ffac 10.1371/journal.pone.0010980 10.1086/655785 10.1086/657082 10.1086/599112 10.1086/587667 10.1093/cid/cir230 10.1111/imr.12063 10.1016/S0140-6736(04)16301-0 10.1086/604716 10.1097/01.aids.0000131375.21070.06 10.1056/NEJMoa1013911 10.1086/518607 10.1007/s12281-011-0064-8 10.1016/S1473-3099(10)70026-8 10.1097/00005792-200205000-00005 10.7326/0003-4819-80-2-176 10.1258/ijsa.2011.010538 10.1086/649858 10.1016/S1473-3099(10)70170-5 10.1097/QAI.0b013e318183181e 10.1056/NEJMoa1014181 |
ContentType | Journal Article |
Copyright | 2014 INIST-CNRS |
Copyright_xml | – notice: 2014 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7T5 7U9 H94 M7N |
DOI | 10.1097/qad.0b013e3283614a8d |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) |
DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1473-5571 |
EndPage | 2099 |
ExternalDocumentID | 10_1097_QAD_0b013e3283614a8d 23525034 27677637 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | South Africa |
GeographicLocations_xml | – name: South Africa |
GrantInformation_xml | – fundername: Howard Hughes Medical Institute |
GroupedDBID | --- .GJ .XZ .Z2 01R 08R 0R~ 1CY 1J1 23M 2WC 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ 85S 8L- AAAXR AAGIX AAHPQ AAJCS AAMOA AAMTA AAPBV AAQKA AARTV AASOK AASXQ AAXQO ABASU ABBUW ABDIG ABFLS ABIVO ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFS ACOAL ACWDW ACWRI ACXNZ ADBBV ADFPA ADNKB AE3 AE6 AEBDS AENEX AFDTB AFFNX AFUWQ AGINI AHRYX AHVBC AIJEX AJIOK AJNYG AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AWKKM BAWUL BOYCO BQLVK BS7 BYPQX C45 CAG COF CS3 DIK DIWNM DUNZO E.X E3Z EBS EJD EX3 F2K F2L F2M F2N F5P FL- FW0 GQDEL H0~ HZ~ IKREB IKYAY IN~ IPNFZ IQODW JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N4W N9A N~7 N~B N~M O9- OAG OAH OBH OCUKA ODA ODMTH OHH OHYEH OJAPA OK1 OL1 OLB OLG OLH OLU OLV OLW OLY OLZ OPUJH OPX ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S SJN T8P TEORI TR2 TSPGW UAP V2I VVN W3M WOQ WOW X3V X3W XJT XXN XYM YFH ZGI ZXP ZZMQN AAAAV AAIQE AAUEB ABJNI ACILI ADGGA ADHPY AEETU AFEXH AHOMT AHQNM AINUH AJNWD AJZMW AMNEI CGR CUY CVF ECM EIF FCALG NPM AAYXX CITATION 7X8 7T5 7U9 H94 M7N |
ID | FETCH-LOGICAL-c482t-b3595376f601ea36228e687157187330429276ac7ffba56daeec332fd5a2f3eb3 |
ISSN | 0269-9370 |
IngestDate | Sat Aug 17 04:19:23 EDT 2024 Fri Aug 16 20:53:44 EDT 2024 Fri Aug 23 03:00:07 EDT 2024 Sat Sep 28 07:51:56 EDT 2024 Thu Nov 24 18:25:55 EST 2022 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 13 |
Keywords | HIV/AIDS Immunopathology Nervous system diseases Mycosis cryptococcal meningitis cryptococcosis-associated immune reconstitution inflammatory syndrome Cryptococcosis Retroviridae Immune reconstitution AIDS Immune deficiency Lentivirus Infection Virus Immune reconstitution syndrome Viral disease Central nervous system disease immune restoration disease Meningitis Human immunodeficiency virus Predictive factor |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c482t-b3595376f601ea36228e687157187330429276ac7ffba56daeec332fd5a2f3eb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doi.org/10.1097/qad.0b013e3283614a8d |
PMID | 23525034 |
PQID | 1490705604 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_1735923440 proquest_miscellaneous_1490705604 crossref_primary_10_1097_QAD_0b013e3283614a8d pubmed_primary_23525034 pascalfrancis_primary_27677637 |
PublicationCentury | 2000 |
PublicationDate | 2013-08-24 |
PublicationDateYYYYMMDD | 2013-08-24 |
PublicationDate_xml | – month: 08 year: 2013 text: 2013-08-24 day: 24 |
PublicationDecade | 2010 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: England |
PublicationTitle | AIDS (London) |
PublicationTitleAlternate | AIDS |
PublicationYear | 2013 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
References | Perfect (R33-9-20210130) 2010; 50 Robertson (R5-9-20210130) 2006; 42 Bicanic (R17-9-20210130) 2009; 49 French (R18-9-20210130) 2000; 1 Bisson (R36-9-20210130) 2008; 49 Haddow (R7-9-20210130) 2010; 10 Muller (R3-9-20210130) 2010; 10 Bicanic (R30-9-20210130) 2007; 45 Bisson (R8-9-20210130) 2013; 56 Makadzange (R10-9-20210130) 2010; 50 Abdool Karim (R11-9-20210130) 2011; 365 Shelburne (R6-9-20210130) 2002; 81 Chang (R26-9-20210130) 2013; 254 Oliver (R27-9-20210130) 2010; 202 Kambugu (R28-9-20210130) 2008; 46 Diamond (R23-9-20210130) 1974; 80 Pappas (R32-9-20210130) 2009; 48 Sungkanuparph (R38-9-20210130) 2009; 49 Bicanic (R24-9-20210130) 2009; 51 French (R4-9-20210130) 2004; 18 Schutzer (R29-9-20210130) 2010; 5 Jarvis (R35-9-20210130) 2012; 26 Lortholary (R19-9-20210130) 2005; 19 Longley (R37-9-20210130) 2008; 47 Torok (R13-9-20210130) 2011; 52 Park (R1-9-20210130) 2009; 23 Blanc (R12-9-20210130) 2011; 365 Wiesner (R16-9-20210130) 2011; 5 Brouwer (R31-9-20210130) 2004; 363 French (R2-9-20210130) 2012; 196 Boulware (R20-9-20210130) 2010; 202 Anekthananon (R21-9-20210130) 2011; 22 |
References_xml | – volume: 56 start-page: 1165 year: 2013 ident: R8-9-20210130 article-title: Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. publication-title: Clin Infect Dis doi: 10.1093/cid/cit019 contributor: fullname: Bisson – volume: 49 start-page: 931 year: 2009 ident: R38-9-20210130 article-title: Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. publication-title: Clin Infect Dis doi: 10.1086/605497 contributor: fullname: Sungkanuparph – volume: 50 start-page: 1532 year: 2010 ident: R10-9-20210130 article-title: Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. publication-title: Clin Infect Dis doi: 10.1086/652652 contributor: fullname: Makadzange – volume: 47 start-page: 1556 year: 2008 ident: R37-9-20210130 article-title: Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. publication-title: Clin Infect Dis doi: 10.1086/593194 contributor: fullname: Longley – volume: 196 start-page: 318 year: 2012 ident: R2-9-20210130 article-title: Immune reconstitution inflammatory syndrome: immune restoration disease 20 years on. publication-title: Med J Aust doi: 10.5694/mja12.10089 contributor: fullname: French – volume: 19 start-page: 1043 year: 2005 ident: R19-9-20210130 article-title: Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. publication-title: AIDS doi: 10.1097/01.aids.0000174450.70874.30 contributor: fullname: Lortholary – volume: 1 start-page: 107 year: 2000 ident: R18-9-20210130 article-title: Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. publication-title: HIV Med doi: 10.1046/j.1468-1293.2000.00012.x contributor: fullname: French – volume: 51 start-page: 130 year: 2009 ident: R24-9-20210130 article-title: Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181a56f2e contributor: fullname: Bicanic – volume: 26 start-page: 1105 year: 2012 ident: R35-9-20210130 article-title: Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. publication-title: AIDS doi: 10.1097/QAD.0b013e3283536a93 contributor: fullname: Jarvis – volume: 42 start-page: 1639 year: 2006 ident: R5-9-20210130 article-title: Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. publication-title: Clin Infect Dis doi: 10.1086/503903 contributor: fullname: Robertson – volume: 23 start-page: 525 year: 2009 ident: R1-9-20210130 article-title: Estimation of the current global burden of cryptococcal meningitis among persons living with HIVAIDS. publication-title: AIDS doi: 10.1097/QAD.0b013e328322ffac contributor: fullname: Park – volume: 5 start-page: e10980 year: 2010 ident: R29-9-20210130 article-title: Establishing the proteome of normal human cerebrospinal fluid. publication-title: PLoS ONE doi: 10.1371/journal.pone.0010980 contributor: fullname: Schutzer – volume: 202 start-page: 962 year: 2010 ident: R20-9-20210130 article-title: Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. publication-title: J Infect Dis doi: 10.1086/655785 contributor: fullname: Boulware – volume: 202 start-page: 1728 year: 2010 ident: R27-9-20210130 article-title: Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. publication-title: J Infect Dis doi: 10.1086/657082 contributor: fullname: Oliver – volume: 48 start-page: 1775 year: 2009 ident: R32-9-20210130 article-title: A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. publication-title: Clin Infect Dis doi: 10.1086/599112 contributor: fullname: Pappas – volume: 46 start-page: 1694 year: 2008 ident: R28-9-20210130 article-title: Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. publication-title: Clin Infect Dis doi: 10.1086/587667 contributor: fullname: Kambugu – volume: 52 start-page: 1374 year: 2011 ident: R13-9-20210130 article-title: Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. publication-title: Clin Infect Dis doi: 10.1093/cid/cir230 contributor: fullname: Torok – volume: 254 start-page: 114 year: 2013 ident: R26-9-20210130 article-title: HIV and co-infections. publication-title: Immunol Rev doi: 10.1111/imr.12063 contributor: fullname: Chang – volume: 363 start-page: 1764 year: 2004 ident: R31-9-20210130 article-title: Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. publication-title: Lancet doi: 10.1016/S0140-6736(04)16301-0 contributor: fullname: Brouwer – volume: 49 start-page: 702 year: 2009 ident: R17-9-20210130 article-title: Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. publication-title: Clin Infect Dis doi: 10.1086/604716 contributor: fullname: Bicanic – volume: 18 start-page: 1615 year: 2004 ident: R4-9-20210130 article-title: Immune restoration disease after antiretroviral therapy. publication-title: AIDS doi: 10.1097/01.aids.0000131375.21070.06 contributor: fullname: French – volume: 365 start-page: 1471 year: 2011 ident: R12-9-20210130 article-title: Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. publication-title: N Engl J Med doi: 10.1056/NEJMoa1013911 contributor: fullname: Blanc – volume: 45 start-page: 76 year: 2007 ident: R30-9-20210130 article-title: Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. publication-title: Clin Infect Dis doi: 10.1086/518607 contributor: fullname: Bicanic – volume: 5 start-page: 252 year: 2011 ident: R16-9-20210130 article-title: Cryptococcus-related immune reconstitution inflammatory syndrome (IRIS): pathogenesis and its clinical implications. publication-title: Curr Fungal Infect Rep doi: 10.1007/s12281-011-0064-8 contributor: fullname: Wiesner – volume: 10 start-page: 251 year: 2010 ident: R3-9-20210130 article-title: Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(10)70026-8 contributor: fullname: Muller – volume: 81 start-page: 213 year: 2002 ident: R6-9-20210130 article-title: Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. publication-title: Medicine (Baltimore) doi: 10.1097/00005792-200205000-00005 contributor: fullname: Shelburne – volume: 80 start-page: 176 year: 1974 ident: R23-9-20210130 article-title: Prognostic factors in cryptococcal meningitis. A study in 111 cases. publication-title: Ann Intern Med doi: 10.7326/0003-4819-80-2-176 contributor: fullname: Diamond – volume: 22 start-page: 665 year: 2011 ident: R21-9-20210130 article-title: Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients. publication-title: Int J STD AIDS doi: 10.1258/ijsa.2011.010538 contributor: fullname: Anekthananon – volume: 50 start-page: 291 year: 2010 ident: R33-9-20210130 article-title: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. publication-title: Clin Infect Dis doi: 10.1086/649858 contributor: fullname: Perfect – volume: 10 start-page: 791 year: 2010 ident: R7-9-20210130 article-title: Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(10)70170-5 contributor: fullname: Haddow – volume: 49 start-page: 227 year: 2008 ident: R36-9-20210130 article-title: The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e318183181e contributor: fullname: Bisson – volume: 365 start-page: 1492 year: 2011 ident: R11-9-20210130 article-title: Integration of antiretroviral therapy with tuberculosis treatment. publication-title: N Engl J Med doi: 10.1056/NEJMoa1014181 contributor: fullname: Abdool Karim |
SSID | ssj0005088 |
Score | 2.4698062 |
Snippet | HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral... OBJECTIVEHIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination... Objective: HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 2089 |
SubjectTerms | Adult AIDS/HIV Anti-Retroviral Agents - administration & dosage Antifungal Agents - administration & dosage Biological and medical sciences Biomarkers CD4 Lymphocyte Count Cerebrospinal Fluid - microbiology Cohort Studies Cryptococcosis - diagnosis Cryptococcosis - pathology Cryptococcus Female General aspects HIV Infections - complications HIV Infections - drug therapy Human immunodeficiency virus Human mycoses Human viral diseases Humans Immune Reconstitution Inflammatory Syndrome - diagnosis Immune Reconstitution Inflammatory Syndrome - pathology Immunopathology Infectious diseases Longitudinal Studies Male Medical sciences Miscellaneous mycoses Mycoses Prospective Studies South Africa Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
Title | Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23525034 https://search.proquest.com/docview/1490705604 https://search.proquest.com/docview/1735923440 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2Mwxu7LLkWDvRVnnixb9qOXbks3OihroW9BvggCix1i56H7N_2n_WRZtlPSsu7FBDu2ZZ_P53w6OhdCPnKhWJhJgDdKfIcHPHLCUHr48NJIBh5Oy3Q28vGvYHbGf5z756PR5SBqaVMnk_TvzryS_5Eq9kGuOkv2DpLtLood-A35YgsJY_tPMp7atEbt_V5epJ0iW631-kvTSEeHja8vVnUJzZeW1aJyZCsRUM2Fzg7RjVPSsg0aMKGPCjhZmvX3XSUN4qPD38NeIJ0zYWrdz6ZmwaKQB9NJx5WBtkouG6nGSpfziLtj38vKxtt80R7KLK_rg6Pu8CCyRCd0QyfNJkN_he4dAaHxgVpjQeSAFLlDHWzqA1iseUON6poWQ6111pm-OzW_qSh8Eh9a1y54E6iHDLPe0tnV_WsGsAtLtAvyuMr8-lXukfsMukwr0Z8nfUF6zW-NG888lM3OjMSnXWPZYj-PVrICJpTpoHLzFKehOqdPyON2jkJjA7inZJQXz8iD4zYK4zn5Y3FHgTs6wB3tcUdLRW_EHTW4o9u4o0PcUYu7F-Ts29fT6cxpu3Y4KQ9Z7SQ61RtmS2Gqn0vwIxbmAablPliQaLxnEROBTIVSifSDTOZ56nlMZb5kCsrBe0n2irLIXxP62ZdBEElQYrBQP3HDhKWhyESSuB5zfTkmjn2b85UpzjK_TYZjsr_1yruTMCABQyvG5IOVwRxqVq-dySIvNxVmyBGMI6YH_Jb_CDw68zh3x-SVEWB_B1122PX4mzsO-S152H9E78hevd7k70GD62S_AeIVL6eyyA |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+and+mycological+predictors+of+cryptococcosis-associated+immune+reconstitution+inflammatory+syndrome&rft.jtitle=AIDS+%28London%29&rft.au=Chang%2C+Christina+C.&rft.au=Dorasamy%2C+Afton+A.&rft.au=Gosnell%2C+Bernadett+I.&rft.au=Elliott%2C+Julian+H.&rft.date=2013-08-24&rft.issn=0269-9370&rft.volume=27&rft.issue=13&rft.spage=2089&rft.epage=2099&rft_id=info:doi/10.1097%2FQAD.0b013e3283614a8d&rft.externalDBID=n%2Fa&rft.externalDocID=10_1097_QAD_0b013e3283614a8d |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-9370&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-9370&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-9370&client=summon |